New tools can propel research in lysosomal storage diseases

Mol Genet Metab. 2023 Dec;140(4):107729. doi: 10.1016/j.ymgme.2023.107729. Epub 2023 Nov 3.

Abstract

Historically, the clinical manifestations of lysosomal storage diseases offered an early glimpse into the essential digestive functions of the lysosome. However, it was only recently that the more subtle role of this organelle in the dynamic regulation of multiple cellular processes was appreciated. With the need for precise interrogation of lysosomal interplay in health and disease comes the demand for more sophisticated functional tools. This demand has recently been met with 1) induced pluripotent stem cell-derived models that recapitulate the disease phenotype in vitro, 2) methods for lysosome affinity purification coupled with downstream omics analysis that provide a high-resolution snapshot of lysosomal alterations, and 3) gene editing and CRISPR/Cas9-based functional genomic strategies that enable screening for genetic modifiers of the disease phenotype. These emerging methods have garnered much interest in the field of neurodegeneration, and their use in the field of metabolic disorders is now also steadily gaining momentum. Looking forward, these robust tools should accelerate basic science efforts to understand lysosomal dysfunction distal to substrate accumulation and provide translational opportunities to identify disease-modifying therapies.

Keywords: CRISPR; Induced pluripotent stem cells (iPSC); Lyso-IP; Lysosomal storage diseases; Lysosome.

MeSH terms

  • Gene Editing
  • Humans
  • Induced Pluripotent Stem Cells*
  • Lysosomal Storage Diseases* / genetics
  • Lysosomal Storage Diseases* / therapy
  • Lysosomes / genetics
  • Lysosomes / metabolism
  • Phenotype